End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
37.79 CNY | +0.67% |
|
+3.17% | -35.88% |
15/05 | Acrobiosystems Co.,Ltd. Approves Cash Dividend for 2023 | CI |
24/04 | Acrobiosystems Co.,Ltd. Proposes Final Cash Dividend for 2023 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-35.88% | 624M | - | ||
+52.28% | 797B | C+ | ||
+40.80% | 628B | B | ||
-6.86% | 351B | C+ | ||
+17.82% | 323B | B- | ||
+11.12% | 300B | C+ | ||
+17.17% | 244B | B+ | ||
+0.94% | 223B | A+ | ||
+5.35% | 163B | C+ | ||
-5.02% | 153B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 301080 Stock
- Ratings Acrobiosystems Co.,Ltd.